LRRK2 and depressive symptom measurement: However, LRRK2 G2385R carriers showed no significant differences in sex distribution, AAO, initial symptoms, motor symptoms and grade of severity, depression, or LED and levodopa-related complications compared to LRRK2 G2385R noncarriers.